The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria
Open Access
- 14 September 2011
- Vol. 118 (10), 2641-2650
- https://doi.org/10.1002/cncr.26544
Abstract
BACKGROUND: We appraised 23 biomarkers previously associated with urothelial cancer in a case-control study. Our aim was to determine whether single biomarkers and/or multivariate algorithms significantly improved on the predictive power of an algorithm based on demographics for prediction of urothelial cancer in patients presenting with hematuria. METHODS: Twenty-two biomarkers in urine and carcinoembryonic antigen (CEA) in serum were evaluated using enzyme-linked immunosorbent assays (ELISAs) and biochip array technology in 2 patient cohorts: 80 patients with urothelial cancer, and 77 controls with confounding pathologies. We used Forward Wald binary logistic regression analyses to create algorithms based on demographic variables designated prior predicted probability (PPP) and multivariate algorithms, which included PPP as a single variable. Areas under the curve (AUC) were determined after receiver-operator characteristic (ROC) analysis for single biomarkers and algorithms. RESULTS: After univariate analysis, 9 biomarkers were differentially expressed (t test; P < .05). CEA AUC 0.74; bladder tumor antigen (BTA) AUC 0.74; and nuclear matrix protein (NMP22) 0.79. PPP included age and smoking years; AUC 0.76. An algorithm including PPP, NMP22, and epidermal growth factor (EGF) significantly improved AUC to 0.90 when compared with PPP. The algorithm including PPP, BTA, CEA, and thrombomodulin (TM) increased AUC to 0.86. Sensitivities = 91%, 91%; and specificities = 80%, 71%, respectively, for the algorithms. CONCLUSIONS: Addition of biomarkers representing diverse carcinogenic pathways can significantly impact on the ROC statistic based on demographics. Benign prostate hyperplasia was a significant confounding pathology and identification of nonmuscle invasive urothelial cancer remains a challenge. Cancer 2011. © 2011 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytologyCancer, 2011
- Association of hyaluronic acid family members (HAS1, HAS2, and HYAL‐1) with bladder cancer diagnosis and prognosisCancer, 2010
- Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of diseaseProteomics – Clinical Applications, 2009
- Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapyBiomarkers, 2009
- Tumor-Specific Urinary Matrix Metalloproteinase Fingerprinting: Identification of High Molecular Weight Urinary Matrix Metalloproteinase SpeciesClinical Cancer Research, 2008
- Human body fluid proteome analysisProteomics, 2006
- Soluble Fas—A promising novel urinary marker for the detection of recurrent superficial bladder cancerCancer, 2006
- Plasma C-Reactive Protein and Risk of Cancer: A Prospective Study from GreeceCancer Epidemiology, Biomarkers & Prevention, 2006
- Development of a High-Throughput Automated Analyzer Using Biochip Array TechnologyClinical Chemistry, 2005
- A Coefficient of Agreement for Nominal ScalesEducational and Psychological Measurement, 1960